{"Symbol": "MACK", "AssetType": "Common Stock", "Name": "Merrimack Pharmaceuticals, Inc", "Description": "Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "One Broadway, Cambridge, MA, United States, 02142", "FullTimeEmployees": "0", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "56063040", "EBITDA": "-41476000", "PERatio": "None", "PEGRatio": "0.07", "BookValue": "1.296", "DividendPerShare": "None", "DividendYield": "0.5771", "EPS": "0.123", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.1888", "ReturnOnEquityTTM": "-0.0799", "RevenueTTM": "0", "GrossProfitTTM": "-9100000", "DilutedEPSTTM": "0.123", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "4", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "3.2938", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "2.3863", "52WeekHigh": "6.41", "52WeekLow": "1.49", "50DayMovingAverage": "3.5925", "200DayMovingAverage": "3.2776", "SharesOutstanding": "13380200", "SharesFloat": "8199413", "SharesShort": "489232", "SharesShortPriorMonth": "483999", "ShortRatio": "10.91", "ShortPercentOutstanding": "0.04", "ShortPercentFloat": "0.0483", "PercentInsiders": "3.355", "PercentInstitutions": "56.869", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0.5771", "PayoutRatio": "0", "DividendDate": "2019-12-23", "ExDividendDate": "2019-12-13", "LastSplitFactor": "1271:1000", "LastSplitDate": "2019-09-06"}